A61K 49/0008
Screening agents using animal models or transgenic animal models or chimeric hosts
Official title: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
A61K49/0008 (Screening agents using animal models or transgenic animal models or chimeric hosts) appears on 872 US grants and 1,649 published applications in this corpus.
Search patents in A61K- Granted patents
- 872
- Published applications
- 1,649
- Assignees
- 765
- Inventors
- 3,289
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 9 | 0 |
| 1997 | 11 | 0 |
| 1998 | 17 | 0 |
| 1999 | 25 | 0 |
| 2000 | 16 | 0 |
| 2001 | 18 | 3 |
| 2002 | 12 | 42 |
| 2003 | 19 | 65 |
| 2004 | 12 | 46 |
| 2005 | 11 | 117 |
| 2006 | 27 | 81 |
| 2007 | 18 | 74 |
| 2008 | 19 | 65 |
| 2009 | 27 | 65 |
| 2010 | 36 | 68 |
| 2011 | 31 | 56 |
| 2012 | 38 | 37 |
| 2013 | 34 | 69 |
| 2014 | 37 | 80 |
| 2015 | 51 | 91 |
| 2016 | 29 | 101 |
| 2017 | 49 | 84 |
| 2018 | 43 | 65 |
| 2019 | 48 | 94 |
| 2020 | 49 | 61 |
| 2021 | 47 | 71 |
| 2022 | 32 | 59 |
| 2023 | 31 | 52 |
| 2024 | 31 | 44 |
| 2025 | 22 | 35 |
| 2026 | 18 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method and composition for treating pain15 Sep 2026US 12,734,172 B2Academia Sinica
- Non-human animals comprising a humanized ACE2 locus11 Aug 2026US 12,702,122 B2Regeneron Pharmaceuticals, Inc.
- Genetically modified non-human animals expressing human EPO4 Aug 2026US 12,696,884 B2Institute for Research in Biomedicine (IRB)
- Method for constructing murine model with mutations in csflr gene and application thereof14 Jul 2026US 12,677,811 B2Beijing Tiantan Hospital, Capital Medical University
- Genetically modified mice having a humanized programmed cell death 1 gene14 Jul 2026US 12,677,813 B2Regeneron Pharmaceuticals, Inc.
- Genetically Modified Non-Human Animals and Methods of Use Thereof8 Oct 2026US 2026/0305588 A1Institute for Research in Biomedicine (IRB)
- Compound pharmaceutical preparation containing oil component comprising polyoxyethylene structure17 Sep 2026US 2026/0273107 A1Chugai Seiyaku Kabushiki Kaisha
- Application of helz2 in drugs for preventing and treating tumors10 Sep 2026US 2026/0265757 A1Jiangsu Concord Biotechnology Co., Ltd
- Muns fusion protein capable of forming microspheres and uses thereof27 Aug 2026US 2026/0248905 A1Universidade De Santiago De Compostela
- Cancer model animal and method for producing same13 Aug 2026US 2026/0231913 A1Orbio Corporation
Most cited
By later US patents
- Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease122US 5,877,399 ARegents of the University of Minnesota · 1999
- Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof93US 8,668,926 B12014
- Monoclonal antibody hPAM491US 7,282,567 B2Immunomedics, Inc. · 2007
- Auristatins having an aminobenzoic acid unit at the N terminus87US 8,288,352 B2Seattle Genetics, Inc. · 2012
- Methods of diagnosing and determining prognosis of colorectal cancer84US 6,682,890 B2Protein Design Labs, Inc. · 2004